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Abstract
Background and Aims—Epstein-Barr virus (EBV) is present in the malignant epithelial cells
of 10% of all gastric adenocarcinomas, however localization of the virus in normal gastrointestinal
mucosa is largely unexplored. In the current study, we measured EBV DNA and localized viral
gene products in gastritis specimens (n=89), normal gastric and colonic mucosa (n=14), Crohn’s
disease (n=9), and ulcerative colitis (n=11) tissues.
Methods—A battery of sensitive and specific quantitative polymerase chain reactions targeted
six disparate regions of the EBV genome: BamH1W, EBNA1, LMP1, LMP2, BZLF1, and
EBER1. EBV infection was localized by EBV-encoded RNA (EBER) in situ hybridization and by
immunohistochemical stains for viral latent proteins LMP1 and LMP2 and for viral lytic proteins
BMRF1 and BZLF1. B lymphocytes were identified using CD20 immunostains.
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Results—EBV DNA was essentially undetectable in normal gastric mucosa but was present in
46% of gastritis lesions, 44% of normal colonic mucosa, 55% of Crohn’s disease, and 64% of
ulcerative colitis samples. Levels of EBV DNA exceeded what would be expected based on the
numbers of B lymphocytes in inflamed tissues, suggesting that EBV is preferentially localized to
inflammatory gastrointestinal lesions. Histochemical staining revealed EBER expression in
lymphoid cells of some PCR-positive lesions. The viral lytic viral proteins, BMRF1 and BZLF1,
were expressed in lymphoid cells of two ulcerative colitis tissues, both of which had relatively
high viral loads by quantitative PCR.
Conclusion—EBV-infected lymphocytes are frequently present in inflamed gastric and colonic
mucosa. Active viral replication in some lesions raises the possibility of virus-related perpetuation
of gastrointestinal inflammation.
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Introduction
Chronic gastritis, which is typically Helicobacter pylori-related, is the earliest precursor
lesion for gastric adenocarcinoma, followed by multistep progression of atrophic gastritis,
intestinal metaplasia, dysplasia, carcinoma in situ, and invasive adenocarcinoma.[1] Epstein-
Barr virus (EBV), a ubiquitous gamma herpesvirus, has been implicated in the pathogenesis
of a variety of diseases including 10% of gastric adenocarcinomas where it is localized to
the malignant epithelial cells.[2] The amount of EBV and its localization in normal gastric
mucosa and gastritis lesions is largely unexplored even though the presence of monoclonal
EBV genomes in gastric cancer suggests that infection occurs before neoplastic
transformation.[3,4] A better understanding of the role of EBV in disease pathogenesis
could be useful in devising better preventive measures and treatments.
Anecdotal evidence of gastritis in infectious mononucleosis patients suggests that EBV can
infect the gastric mucosa at the time of primary infection.[5–8] Interestingly, the proximal
segment of the stomach is more inflamed, and this is the same segment where EBV-related
carcinomas commonly arise. Virions are periodically shed in saliva of most healthy adults,
suggesting one route of viral entry to the stomach is by swallowing, while another route is
by hematogenous spread of the occasional infected B lymphocytes that are present in nearly
all adults.[2,9] In older adults, polyclonal or monoclonal EBV-driven lymphoproliferations
are thought to result from age-related decline in immune response.[10] EBV-related mucosal
ulcers have been described in immunosuppressed individuals.[11]
Still unknown is the extent to which EBV is found in normal gastric mucosa and in the full
range of gastritis lesions. Its presence in dysplasia and in chronic atrophic gastritis has been
reported,[4,12–14] but there are conflicting data regarding frequency of infection and
localization of EBV in various premalignant lesions.[3,4,12,14–22]
An interesting case report describes a lymphoepithelioma-like carcinoma arising in the
sigmoid colon of a patient with ulcerative colitis in which EBER was localized to the
malignant epithelial cells and also to many tumor-infiltrating lymphocytes.[23] Cross-
reactive humoral immune responses to EBV antigens are proposed as a mechanism of
autoimmunity, as is infection-driven persistence of autoreactive B cells.[24–28] It is feasible
that active viral replication could also contribute to pathogenesis of inflammatory processes.
Colonic mucosa tends to harbor more chronic inflammatory cells than does gastric mucosa,
suggesting that levels of EBV DNA might be different in these two anatomic sites
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depending on the proportion of infected B cells that reside there. The extent to which EBV
levels correlate with levels of inflammatory infiltrate in various tissues could help solve
whether EBV is an innocent bystander or is contributing in a pathogenic fashion to
inflammatory lesions. Furthermore, if EBV localizes to benign epithelial cells, it could
implicate EBV at an earlier stage of carcinogenesis than was previously recognized.
In this study, we examined the prevalence of EBV infection in normal and inflamed gastric
and colonic mucosa using a battery of quantitative polymerase chain reaction (Q-PCR)
assays targeting six disparate regions of the EBV genome. The rationale for using multiple
Q-PCR assays was to confirm the specificity of positive results and to more precisely
quantify viral load by targeting multiple genomic loci.[29] When EBV was detected by Q-
PCR, infection was further characterized as latent or lytic using histochemical assays that
also pinpoint the cell type that was infected. The number of B lymphocytes in each mucosal
sample was estimated using CD20 immunohistochemical stains so that viral loads could be
interpreted in the context of cell counts.
Materials and Methods
Patient Tissue and Blood Samples
We studied consecutive formalin-fixed, paraffin-embedded tissues from the clinical archives
of two hospitals, the University of North Carolina Hospitals in Chapel Hill, and the Western
Regional Hospital in Santa Rosa de Copan, Honduras. The gastritis tissues were from three
subsets of gastritis patients-- 6 adults from Honduras, 33 adults from the United States
(U.S.), and 50 children (age 2 months to 20 years) from the U.S. To explore gastritis lesions
in association with cancer, the U.S. adult gastritis lesions were identified within gastrectomy
specimens from patients with gastric adenocarcinoma. The colitis lesions were from U.S.
inflammatory bowel disease patients-- 9 with Crohn’s disease, and 11 with ulcerative colitis.
All studies were done with approval of our Institutional Review Board.
Residual normal gastric mucosa was obtained, with informed consent, from five patients
undergoing gastric bypass surgery. Paraffin blocks were prepared following fixation in 10%
neutral buffered formalin. Additional controls included paraffin-embedded blocks of normal
colonic mucosa from 9 patients, and meningioma tumors from 11 patients. Meningiomas
were chosen as a control because they are not EBV-related and they have minimal
lymphocytic infiltrate. Paraffin sections were placed on coated glass slides for histochemical
stains, or placed in a microfuge tube for DNA extraction as previously described.[29] Whole
blood samples (n=10) from healthy donors served as controls for baseline levels of
circulating EBV DNA. Total DNA was extracted from 200μl of blood using the QIAmp
Blood Kit (Qiagen Inc., Valencia, CA) following the manufacturer’s protocol. Purified DNA
was eluted into 50μl of AE buffer (Qiagen).
Quantitative real-time PCR as a measure of EBV viral load
A battery of Q-PCR assays targeting six disparate regions of the EBV genome was used to
measure EBV viral load in tissue and blood samples. We previously developed five of these
Q-PCR assays targeting BamH1W, EBNA1, LMP1, LMP2, and BZLF1 regions of the EBV
genome,[29] while the sixth assay targeting EBER1 DNA was developed by Ling et al.[30]
A Q-PCR assay targeting the human APOB gene was used to control for efficacy of DNA
extraction and to normalize for the number of cells in the sample.[29]
Q-PCR was performed and products were detected using ABI Prism 7900 or 7500 Real-
Time PCR instruments and Sequence Detection System software (Applied Biosystems) as
previously described.[29] Briefly, each 25uL reaction contained: 1X TaqMan Universal
Master Mix, forward and reverse primers (15pmol each) and TaqMan probe (10pmol). The
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assays targeting LMP1 and BZLF1 used 30pmol each of the forward and reverse primers.
Template volume was 1uL of DNA from each paraffin-embedded tissue, and 5uL of DNA
from whole blood. Thermocycling conditions were: 50°C for 2 minutes, 95°C for 10
minutes, and then 95°C for 15 seconds and 60°C for 1 minute for 40 cycles. A standard
curve was generated using serial 10-fold dilutions of Namalwa DNA (two copies of EBV
per cell) varying from 50,000 copies to 0.5 copies of EBV DNA. This curve was acceptable
if a difference of 3.3 +/− 0.3 cycles was demonstrated between each of the 10-fold dilutions,
and if the correlation coefficient was at least 0.99. To check for amplicon contamination,
every run contained at least two “no template” controls in which nuclease-free H2O was
substituted for template. All experimental samples were run in duplicate and a mean viral
load was calculated based on the ratio of the copies of EBV to cellular APOB in a given
sample multiplied by 100,000, which represented the number of copies of EBV DNA per
100,000 cells. For purposes of statistical analysis, samples with no measurable EBV DNA
were reported as having a viral load of zero.
EBV-encoded RNA in situ hybridization
EBER in situ hybridization is considered the gold standard assay for detecting latent EBV
infection. A manual method of EBER staining relied on a fluorescein-labeled
oligonucleotide probe targeting EBER RNA (Biogenex, San Ramon, CA) and the Super-
Sensitive Poly-HRP ISH Non-Biotin Detection Kit (Biogenex) with methyl green
counterstain. An automated EBER stain method was carried out on the Ventana Benchmark
in situ hybridization system according to the manufacturer’s protocol. An oligo d(T) probe
targeting poly(A) tails of mRNA served as a control for RNA preservation. No significant
discrepancies were observed between the manual and automated EBER staining procedures
among 56 samples tested by both methods. A tissue was considered EBER-negative if no
EBER signal was seen in any nuclei. EBER-positive cell types were characterized by
cytomorphology.
LMP1, LMP2A, BMRF1, and BZLF1 expression by immunohistochemistry
Immunohistochemical analysis for the latent viral proteins, LMP1 and LMP2, was
performed as described[31] using citrate antigen retrieval and the anti-EBV LMP1 CS1-4
cocktail of mouse monoclonal antibodies (1:100, Dako, Carpinteria, CA) or the LMP2A
E411 rat monoclonal antibody (1mg/ml, Asencion, Munich, Germany). EBER-positive
Hodgkin lymphoma slides served as positive controls for both assays. Results were
interpreted microscopically by localizing the chromagen to the cytoplasm and membrane of
target cells.
Immunohistochemical analysis of the lytic EBV proteins, BMRF1 and BZLF1, was
performed using citrate antigen retrieval and BMRF1 G3-E31 antibody (1:200, Research
Diagnostics, Inc., Flanders, NJ) or BZLF1 BZ.1 antibody (1:25, Dako). Sections were
incubated with primary antibody for 30 minutes at 37°C using the manufacturer’s blocking
and detection protocols in the Super-Sensitive Non Biotin HRP Detection Kit (Biogenex).
Bound antibody was detected by diamino-benzidine chromogen (Biogenex) and tissues were
counter-stained with hematoxylin (Dako) to permit microscopic nuclear localization of the
chromagen. Oral hairy leukoplakia paraffin sections served as the positive control.
Estimation of B lymphocyte Number using CD20 Immunohistochemistry
Immunohistochemical analysis of CD20 was performed using prediluted CD20 (L26)
primary antibody (Chemicon International, Temecula, CA) and the IHC Select
Immunophosphatase Secondary Detection system (Chemicon) with Fast Red chromogen.
Conventional light microscopy was used to estimate the proportion of cells that expressed
CD20 across nine different 40X fields.
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Levels of EBV DNA in “Normal” Tissue
In order to determine baseline levels of EBV in healthy individuals, we examined whole
blood from healthy donors (n=10), normal gastric mucosa (n=5), and normal colon mucosa
(n=9) for the presence of EBV DNA using a battery of six EBV Q-PCR assays (Table 1). As
expected, extremely low level EBV DNA was detected in the peripheral blood of healthy
donors (mean viral load= 0.7 EBV DNA copies/100,000 nucleated cells). EBV DNA was
rarely detected in normal gastric mucosa in keeping with the paucity of lymphoid tissue in
the stomach (Table 2). Only 1/5 (20%) normal gastric mucosa had detectable EBV DNA,
and that case had <1 copy of viral DNA per 100,000 cells (about one in a million cells).
EBER in situ hybridization was completely negative in normal gastric mucosa, while 4/9
normal colon samples (44%) had detectable EBER-positive lymphocytes in correlation with
detectable EBV DNA by Q-PCR in the same four colonic mucosa samples (average viral
load = 2 EBV DNA copies/100,000 cells). It was concluded that EBV is present at low
levels in normal whole blood, stomach, and colon tissues of immunocompetent individuals.
EBV Levels in Gastritis Lesions
Gastritis lesions (n=89) from three different clinical settings (cancer-associated, adult, and
pediatric) were screened using a battery of six Q-PCR assays targeting disparate regions of
the EBV genome. EBV DNA was detected by at least one of the Q-PCR assays in 21/33
(64%) cancer-associated gastritis lesions, in 5/6 (83%) adult gastritis lesions, and in 15/50
(30%) pediatric gastritis lesions. The mean viral load for each type of gastritis was 41, 32,
and 47 EBV DNA copies/100,000 cells, respectively, with an average of 40 EBV DNA
copies/100,000 cells.
The EBV viral loads for cancer-associated gastritis were fairly consistent across the six Q-
PCR assays. See Figure 1. Interestingly, 3/33 (9%) cancer-associated gastritis samples
(cases # 3, 6, and 7) had detectable EBV DNA by all six Q-PCR assays and were located
adjacent to EBER-positive gastric cancers. It should be clarified that no tumor was seen by
microscopy in these gastritis lesions that were sampled from the same stomach where gastric
adenocarcinoma was present. The remaining 30 cancer-associated gastritis lesions were
adjacent to EBER-negative cancers, and about half of these gastritis lesions had measurable
EBV loads by at least one Q-PCR assay. When EBV DNA was detected by only one Q-PCR
assay, there was a preference for detecting the BZLF1 region of the viral genome,
suggesting that either this assay is more sensitive than the other five assays or that it detects
a naturally amplified DNA independent of the complete viral genome.
To help resolve the particular cell types that were infected, EBER in situ hybridization was
performed on each gastritis case that had detectable EBV DNA by at least one Q-PCR assay
(n=41). Rare EBER-positive cells were observed in 7/21 cancer-associated gastritis and 3/5
adult gastritis tissues. In contrast, no EBER expression was observed in the pediatric
gastritis cases. When present, the EBER signal was localized to small to medium lymphoid
cells and was never seen in epithelial cells or stromal cells. (See Figure 2.) This suggests
that the amplifiable EBV DNA was derived, at least in part, from infected lymphocytes.
Detection of EBV in Crohn’s Disease and Ulcerative Colitis Tissues
Crohn’s colitis (n=9) and ulcerative colitis (n=11) tissues were tested for EBV using the 6
Q-PCR assays and EBER in situ hybridization to quantify and localize EBV infection. EBV
DNA was detected by at least one Q-PCR assay in 5/9 (55%) Crohn’s disease and 7/11
(64%) ulcerative colitis tissues. The overall mean viral load was higher in ulcerative colitis
(176 EBV DNA copies/100,000 cells) compared to Crohn’s disease (27 EBV DNA copies/
Ryan et al. Page 5










100,000 cells) or gastritis (40 EBV DNA copies/100,000 cells) but these differences were
not statistically significant.
EBER-positive lymphoid cells were observed in 1/5 Crohn’s disease samples and in 5/7
ulcerative colitis samples. Furthermore, EBER localization was limited to rare scattered
lymphoid cells in the Crohn’s disease, while 3 of the ulcerative colitis samples had strikingly
positive EBER signal in as many as 20% of lymphocytes. EBER was not seen in epithelial
cells or in other stromal cell types besides small to large lymphoid cells.
Histochemical Localization of Latent and Lytic EBV Proteins
A possible explanation for the observed increased viral load in gastritis and colitis compared
to normal gastric and colonic mucosa could be infiltrating chronic inflammatory cells, thus
escalating the frequency at which random EBV-infected B cells happen to be present. An
alternate hypothesis is that EBV infected lymphoid cells are preferentially found in these
lesions and they might even contribute to pathogenesis of these diseases. Higher viral loads
could be a consequence of viral replication by which cells enter the lytic phase of infection
and replicate the viral genome. To address these possibilities, immunohistochemistry for
LMP1 and LMP2A was performed to detect latent viral proteins, and immunohistochemistry
for BMRF1 and BZLF1 was performed to detect lytic viral proteins. Neither latent nor lytic
EBV proteins were expressed in normal gastric or colon mucosa, gastritis, or Crohn’s
disease samples. However, BMRF1 and BZLF1 proteins were observed in scattered
lymphoid cells in two of five ulcerative colitis cases, and both cases also expressed EBER in
many lymphocytes. See Figure 3. No latent or lytic gene expression was seen in non-
lymphoid cells. These results suggest that high viral DNA levels in some ulcerative colitis
lesions could result in part from EBV replication and in part from relatively high numbers of
latently infected lymphocytes. In contrast, the lower levels of EBV found in gastritis and
Crohn’s disease lesions appear to derive from latently infected lymphoid cells.
Sampling error may account for the failure to localize latent or lytic viral infection in some
lesions in which EBV DNA was amplifiable. Extracellular EBV DNA cannot be excluded as
a source of PCR amplifiable viral DNA.
B lymphocytes in normal or chronically inflamed gastrointestinal epithelium
To study whether EBV viral load elevation is merely the result of higher numbers of
infiltrating B lymphocytes, we estimated the number of B cells in normal versus inflamed
tissue using an immunohistochemical stain for CD20. First, a series of meningiomas (n=11)
were studied because they represent a control tissue that has very little inflammatory cell
infiltrate and is not EBV-related. It is thought that this tumor of the membranes lining the
brain or spinal cord harbors few inflammatory cells (beyond those transiting inside blood
vessels) as a consequence of the tight capillary structure of the “blood-brain barrier”. The six
Q-CPR assays and EBER in situ hybridization were applied, and EBV DNA was detected by
at least one Q-PCR assay in 2/11 meningiomas (18%). The viral load (0.3 EBV DNA
copies/100,000 cells) was similar to that of whole blood from healthy individuals (0.7 EBV
DNA copies/100,000 cells). No EBER-positive cells were observed in meningioma tissues.
B lymphocytes accounted for less than 0.5% of cells in meningioma specimens (mean=4
CD20+ cells in 40X field). These findings provide a baseline by which to compare measured
values in normal and inflamed gastrointestinal tissues.
Next, B cells were quantified in mucosal specimens of the colon and stomach. Compared
with normal colon, there were more B lymphocytes in Crohn’s disease (mean=78 CD20+
cells per 40X field) and ulcerative colitis (mean=75 CD20+ cells per 40X field), with an
estimated 4% of the cells in the Crohn’s disease and ulcerative colitis samples being B
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lymphocytes. In contrast, approximately 2% of the cells in the gastritis, normal gastric
mucosa, and normal colon samples were B lymphocytes (mean= 41, 33, and 49 CD20+ cells
per 40X field, respectively). These results, combined with viral loads described above,
suggest that higher EBV viral loads in inflamed tissues reflect, at least in part, an increase in
the number of infiltrating B lymphocytes. However, the proportional increase in EBV levels
was far higher than the proportional increase in B cell infiltrates for inflamed versus normal
mucosa, implying that EBV level is not solely dependent on B cell number. This result
suggests that EBV is preferentially localized to inflammatory lesions of the stomach and
colon beyond what is expected if EBV were an innocent bystander in random B
lymphocytes.
Helicobacter pylori status
Helicobacter pylori serologic testing had been performed clinically in only fraction of the
gastritis patients, so we performed microscopy to look for evidence of bacteria on the
mucosal surface consistent with helicobacter infection. Evidence of infection was found in
5/6 Honduran adult gastritis patients, 9/50 U.S. pediatric gastritis patients, and only 1/33
U.S. patients with concomitant gastric cancer. The latter result is likely an underestimate of
the true infection status given the reported loss of bacterial organisms as cancer develops.[1]
A more systematic approach to bacterial detection would be required in order to explore
association with EBV in normal and inflamed gastric mucosae.
Discussion
This study used state-of-the-art molecular and histochemical methods to examine the
prevalence of EBV in gastrointestinal tissues and controls. In healthy individuals, there are
estimated to be approximately 1 to 50 viral genome-carrying cells per million blood cells.[9]
In our own series of 10 healthy adult blood donors, we measured an EBV viral load of
approximately 7 EBV DNA copies per million nucleated blood cells. In paraffin-embedded
tissue, our battery of six Q-PCR assays confirmed presence of the EBV genome when
multiple assays were positive, and the fairly consistent viral loads across multiple positive
results helped assure the accuracy of viral DNA measurements.
Since EBV is a ubiquitous virus that infects the majority of humans without major adverse
health consequences,[2] it is important to distinguish between normal background levels of
EBV and abnormally increased levels of EBV that could suggest pathogenicity. This study
advances the field by showing that 1) EBV DNA levels vary with the degree of chronic
inflammation, 2) EBV is restricted to lymphoid cells in benign gastrointestinal mucosa, 3)
active viral replication can occur in lymphoid cells of ulcerative colitis, and 4) EBV DNA
levels are disproportionately high in inflamed gastrointestinal mucosa compared to normal
mucosa, even after accounting for differences in the numbers of B lymphocytes that are
present. Overall, these findings suggest that EBV infection may contribute to the
pathogenesis of gastritis and colitis.
It is important to study EBV infection in the stomach because of the potential link to EBV-
related gastric cancer. We found that the EBV viral load in normal gastric mucosa is
extremely low (<1 EBV DNA copy/100,000 cells), similar to that of whole blood from
healthy donors. Likewise, histochemical stains revealed no evidence of EBV infection in
normal gastric mucosa, and rare EBER-expressing lymphoid cells in a subset of PCR-
positive gastritis lesions which we interpret as being related to occasional infected cells in
either the scant inflammatory infiltrate or the intravascular compartment. We cannot exclude
the possibility that virions swallowed with saliva could have adhered to the surface of
gastric mucosa and given rise to the EBV DNA that was measured.
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It is important to know if EBV is routinely present in gastritis or whether it enters the
mucosa in concert with the onset of EBV-associated neoplasia. Support for early infection
comes from Levine et al, who found that EBV serologic titers are elevated prior to diagnosis
of EBV-related gastric cancer.[32] Tissue-based studies have been inconsistent on the extent
of EBV in gastritis lesions.[13,14,16,17,21,22] Yanai et al reported finding EBV DNA in
rare benign epithelial cells by in situ hybridization in three of 20 cases (15%) of chronic
atrophic gastritis.[14] A second group supported this finding, while a third group could not
confirm the finding even when using similar methods.[18,19] Zur Hausen et al suggested
that EBV infection was a late event during carcinogenesis based on lack of detectable EBV
in intestinal metaplasia or dysplasia.[33] However, others have localized EBER transcripts
to dysplastic lesions, suggesting that EBV infection correlates with the onset of neoplastic
cell growth.[3,4]
In the current study, EBV DNA was detected in many gastritis specimens at levels higher
than normal gastric mucosa, and rare EBER-expressing lymphocytes were identified as a
potential source of the virus. EBER was not seen in benign gastric epithelial cells, a finding
that is supported by several other investigators.[4,5,16,34–37] Nor was active viral
replication implicated as a source of the viral DNA, since neither BZLF1 nor BMRF1 were
expressed in gastritis. While further work is required to more completely understand sources
of viral DNA, our findings implicate latently infected lymphocytes as a reservoir. If
expressed at all, LMP1 and LMP2A protein must be at low level or in such rare cells as to
be undetected by our immunohistochemical staining procedure.
In terms of geographic variation, the Honduran gastritis tissues were more frequently EBV
infected than were the U.S. adult or U.S. pediatric gastritis cases (83%, 64%, and 30% of
cases harboring EBV DNA, respectively). This may be clinically relevant because
Hondurans have a very high rate of Helicobacter pylori infection and also a high rate of
gastric cancer.[38,39] Both EBV and Helicobacter pylori are classified as class 1
carcinogens by the World Health Organization, and a substantial fraction of individuals
become co-infected by adulthood.[40,41] These two pathogens could potentially synergize
to cause and perpetuate chronic gastritis.[21] For example, if an EBV-infected B cell were
activated by exposure to a foreign epitope of Helicobacter pylori, then terminal
differentiation of the host B cell would trigger the virus to switch from the latent to lytic
phase of its life cycle, thus inciting further inflammation as the immune system recognizes
and fights both infections. The resulting cytokine response could trigger infiltration of more
lymphocytes, a few of which are EBV infected, thus perpetuating the cycle of infection and
inflammation that manifests clinically as chronic gastritis. A proposed model for this process
is depicted in Figure 4. An analogous process could occur in the colon where enteric
bacterial pathogens are sources of antigenic stimuli.
To date, EBV has not been shown to be involved in colorectal carcinoma.[42] But EBV and
other herpes family viruses, CMV and HHV6, have been implicated in the pathogenesis of
inflammatory bowel disease.[43–50] Two groups describe finding PCR-amplifiable EBV
DNA in inflammatory bowel disease tissues.[44,48] Yanai et al localized EBER expression
to non-epithelial cells (B lymphocytes and histiocytic cells) in both Crohn’s disease and
ulcerative colitis tissues.[47] Gehlert et al described preferential localization of EBER-
expressing cells to zones of active inflammation in both diseases.[45] However, Spieker et al
showed that EBER-expressing lymphocytes were only slightly more prevalent in Crohn’s
disease than in chronic appendicitis or diverticulitis, implying no special relation of the virus
with Crohn’s colitis.[43] Recent studies have shown that EBV-positive lymphocytes
accumulate transmurally in ulcerative colitis, suggesting the colon as a potential site for
EBV replication and transmission.[43,45]
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Extending previous findings, the current study detected EBV DNA in 55% of Crohn’s
disease and 64% ulcerative colitis tissues, with mean viral loads significantly higher in these
lesions than in normal colon. Some ulcerative colitis lesions contained abundant EBER-
expressing lymphocytes with evidence of active lytic viral replication. Histochemical stains
revealed no cell type other than lymphocytes harboring EBV in normal colonic tissue or in
any of the other benign tissues that we examined. This implies that infection of benign
epithelial cells is very rare or absent.
We further examined whether the differences in EBV viral load among tissue types merely
reflect the proportion of B lymphocytes present in those tissues. After accounting for the
number of infiltrating B lymphocytes, the excess EBV DNA found in gastritis samples
seems beyond the level expected if the virus were merely a passenger in random infiltrating
B lymphocytes. Interestingly, the EBV viral load for ulcerative colitis was greater than for
Crohn’s disease, even though the percentage of B lymphocytes (4%) was similar. Ulcerative
colitis lesions harbor T helper 2 (Th2) cells producing cytokines (e.g. IL5, IL6) known to be
growth factors for EBV-infected lymphocytes.[51,52] Active viral replication may further
contribute to high viral loads. Since viral replication can be inhibited by nucleoside analogs
such as gancyclovir,[53] it is worth considering whether antiviral agents might diminish
mucosal inflammation and reduce risk of carcinogenesis. Other antiviral strategies include
unmasking immunogenic viral peptides, infusing EBV-specific cytotoxic T cells, or
thwarting downstream effects of viral infection.[54,55] Vaccination could also be
considered as an approach to preventing inflammatory sequelae.
A limitation of our study is the confounding variables of two geographic sites, two age
groups, and presence or absence of concomitant cancer. Further exploration of EBV and
other elements of the virome are required to understand the epidemiology of virus-related
inflammation and pre-neoplasia in the gastrointestinal tract.[56,57] Of special interest is the
“field effect” by which cancer seems to arise in mucosa that already has some molecular
fingerprints of malignancy.[58] Indeed, viral infection could represents one factor among the
accumulating epigenetic and genetic changes along the pathways of carcinogenesis. Once
cancer develops, malignant cells could potentially secrete factors influencing the function of
surrounding tissues. In this regard, it is interesting to note our consistent detection of all 6
segments of the EBV genome in gastritis lesions located adjacent to EBV-related gastric
cancer. A possible source of PCR template is inter-cellular transmission of DNA in
exosomes or other microvesicles.[59,60]
In summary, our work shows that EBV levels are higher in inflamed gastrointestinal mucosa
compared to normal counterparts. By histochemical analysis, latent and lytic EBV infection
was localized to lymphocytes but not to benign epithelial cells of inflamed gastric and
colonic mucosa. Further work is warranted to understand the role of EBV in pathogenesis of
gastritis and colitis and to explore how antiviral strategies could ameliorate inflammation
and associated cancer predisposition.
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Figure 1. Trends of EBV Viral Load in gastritis lesions
A) Some cancer-associated gastritis tissues had EBV DNA detected by 3 or more Q-PCR
assays (left panel) while others were detected by only 1 or 2 Q-PCR assays (right panel). B)
Honduran adult gastritis tissues (left panel) consistently had detectable EBV DNA by any of
5 Q-PCR assays but had unamplifiable LMP1 genes, suggesting that the LMP1 assay is less
sensitive than the other 5 assays, whereas pediatric gastritis tissues (right panel) had
preferential detection of the BamH1W and BZLF1 regions of EBV DNA.
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Figure 2. EBV is localized to lymphoid cells in inflamed gastric tissues
Epstein-Barr virus encoded RNA (EBER) is expressed in rare lymphoid cells as shown by
nuclear localization of purple signal to a single small round nucleus in the inflammatory cell
infiltrate associated with each of two gastric adenocarcinomas. The malignant epithelial
cells and stromal cells were EBER-negative in both cases. (200x)
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Figure 3. Immunohistochemical stains reveal lytic EBV infection in ulcerative colitis
Active EBV replication occurs in scattered lymphoid cells of an ulcerative colitis as shown
by nuclear localization of the viral replicative proteins BZLF1 (A), and BMRF1 (B). (200x)
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Figure 4. A model for synergistic cooperation between Helicobacter pylori and EBV infection in
the etiology of gastritis
Helicobacter pylori or similar inflammatory stimulus recruits lymphocytes to the gastric
mucosa. If an EBV-infected B cell were activated by exposure to foreign bacterial antigen,
then terminal differentiation of the host B-cell would trigger the virus to switch from latent
to lytic phases of infection, thus inciting more inflammation as the immune system
recognizes and fights active viral infection. The resulting cytokine response triggers
infiltration of even more lymphocytes, a few of which are incidentally EBV infected. This
inflammation, along with infection of naïve B cells, perpetuates the cycle of infection and
inflammation that manifests clinically as chronic gastritis.
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